The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C. Wheeler, Hiddo J.L. Heerspink, Hans Furuland et al.|Nephrology Dialysis Transplantation|2020Cited by 189
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trialJohannes F.E. Mann, Katherine R. Tuttle, Peter Rossing et al.|Nature Medicine|2024Cited by 152
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trialEllen M. Apperloo, Hiddo J.L. Heerspink, José Luis Górriz et al.|Nature Medicine|2024Cited by 95
Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney diseaseW Bakker, J W Rood, Hiddo J.L. Heerspink et al.|Nephrology Dialysis Transplantation|2025Cited by 18
Effects of Semaglutide on Kidney Parameters in Patients with Obesity and Nondiabetic CKDHiddo Jan L. Heerspink, José Luis Górriz, Ellen M. Apperloo et al.|Journal of the American Society of Nephrology|2024Cited by 0